Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

OBJECTIVE: To evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib versus placebo in Japanese patients with rheumatoid arthritis (RA). METHODS: In this multicentre, double-blind, parallel-group, placebo-controlled phase III study, patients with RA and inadequate resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Tanaka, Sakae, Kawakami, Atsushi, Iwasaki, Manabu, Katayama, Kou, Rokuda, Mitsuhiro, Izutsu, Hiroyuki, Ushijima, Satoshi, Kaneko, Yuichiro, Shiomi, Teruaki, Yamada, Emi, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788880/
https://www.ncbi.nlm.nih.gov/pubmed/31350269
http://dx.doi.org/10.1136/annrheumdis-2019-215164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788880/
https://www.ncbi.nlm.nih.gov/pubmed/31350269
http://dx.doi.org/10.1136/annrheumdis-2019-215164

Ejemplares similares